AU2018385697B2 - Stabilized peptide-mediated targeted protein degradation - Google Patents

Stabilized peptide-mediated targeted protein degradation Download PDF

Info

Publication number
AU2018385697B2
AU2018385697B2 AU2018385697A AU2018385697A AU2018385697B2 AU 2018385697 B2 AU2018385697 B2 AU 2018385697B2 AU 2018385697 A AU2018385697 A AU 2018385697A AU 2018385697 A AU2018385697 A AU 2018385697A AU 2018385697 B2 AU2018385697 B2 AU 2018385697B2
Authority
AU
Australia
Prior art keywords
peptide
protein
seq
degron
chimera
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018385697A
Other languages
English (en)
Other versions
AU2018385697A1 (en
Inventor
Gregory H. Bird
James E. Bradner
Henry D. HERCE
Ann Maurine MORGAN
Rida MOURTADA
Loren D. Walensky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2018385697A1 publication Critical patent/AU2018385697A1/en
Application granted granted Critical
Publication of AU2018385697B2 publication Critical patent/AU2018385697B2/en
Priority to AU2024200512A priority Critical patent/AU2024200512B2/en
Priority to AU2026201801A priority patent/AU2026201801A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018385697A 2017-12-15 2018-12-14 Stabilized peptide-mediated targeted protein degradation Active AU2018385697B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024200512A AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation
AU2026201801A AU2026201801A1 (en) 2017-12-15 2026-03-10 Stabilized Peptide-Mediated Targeted Protein Degradation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599608P 2017-12-15 2017-12-15
US62/599,608 2017-12-15
PCT/US2018/065784 WO2019118893A1 (en) 2017-12-15 2018-12-14 Stabilized peptide-mediated targeted protein degradation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200512A Division AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation

Publications (2)

Publication Number Publication Date
AU2018385697A1 AU2018385697A1 (en) 2020-04-30
AU2018385697B2 true AU2018385697B2 (en) 2023-11-09

Family

ID=65201672

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018385697A Active AU2018385697B2 (en) 2017-12-15 2018-12-14 Stabilized peptide-mediated targeted protein degradation
AU2024200512A Active AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation
AU2026201801A Pending AU2026201801A1 (en) 2017-12-15 2026-03-10 Stabilized Peptide-Mediated Targeted Protein Degradation

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024200512A Active AU2024200512B2 (en) 2017-12-15 2024-01-29 Stabilized peptide-mediated targeted protein degradation
AU2026201801A Pending AU2026201801A1 (en) 2017-12-15 2026-03-10 Stabilized Peptide-Mediated Targeted Protein Degradation

Country Status (7)

Country Link
US (2) US20200354413A1 (https=)
EP (1) EP3724216A1 (https=)
JP (3) JP2021506814A (https=)
CN (2) CN112119085B (https=)
AU (3) AU2018385697B2 (https=)
CA (1) CA3078682A1 (https=)
WO (1) WO2019118893A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
CN111393519B (zh) * 2019-11-21 2022-11-08 中国药科大学 作为krasg12c/sos1抑制剂的新型订书肽及其用途
WO2021141662A1 (en) * 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
EP4142766A2 (en) * 2020-04-27 2023-03-08 Dana Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
US20220025341A1 (en) * 2020-05-29 2022-01-27 Massachusetts Institute Of Technology Minimal peptide fusions for targeted intracellular protein degradation
CN115702026A (zh) 2020-06-23 2023-02-14 基因泰克公司 大环化合物及其使用方法
CN116406303B (zh) * 2020-09-04 2025-07-29 孔二艳 将gfap氨基酸位点作为神经退行性疾病治疗靶标的应用
AU2021360898A1 (en) 2020-10-14 2023-03-23 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
GB202018608D0 (en) * 2020-11-26 2021-01-13 Zentraza Ltd Adhesive peptides
US20240051999A1 (en) * 2020-12-18 2024-02-15 John Innes Centre Methods for targeted protein degradation
CN117642397A (zh) * 2021-03-16 2024-03-01 上海睿跃生物科技有限公司 经修饰的蛋白质和蛋白质结合剂
CN113845598B (zh) * 2021-09-18 2023-06-30 中国人民解放军海军军医大学 一种蛋白质靶向嵌合体降解mdm2/mdmx蛋白的订书肽缀合物及其用途
US20230257725A1 (en) * 2021-10-22 2023-08-17 Massachusetts Institute Of Technology Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3
US20250179124A1 (en) * 2022-02-07 2025-06-05 Ubiquitx Beta-catenin protein degradation
WO2023203127A1 (en) 2022-04-20 2023-10-26 Vib Vzw Alphabody-based degrader molecules
US20260083722A1 (en) * 2022-05-19 2026-03-26 The Scripps Research Institute Bifunctional degraders comprising electrophilic protacs that engage dcaf1 and pharmaceutical compositions comprising the same
EP4705323A1 (en) * 2023-05-05 2026-03-11 Senti Biosciences, Inc. Modified degron polypeptides and uses thereof
CN121925410A (zh) 2023-09-29 2026-04-24 第一三共株式会社 3-苯基丙胺衍生物
CN117904060B (zh) * 2023-12-21 2024-09-24 上海大学 一种基于parkin的靶向蛋白泛素化降解剂及其制备方法和应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
EP0958305B1 (en) 1996-07-05 2008-06-04 Cancer Research Technology Limited Inhibitions of the interaction between p53 and mdm2
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
JP3786832B2 (ja) 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 分解性のヘテロ二官能性ポリ（エチレングリコール）アクリレート及びそれから誘導されるゲル及び複合体
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
EP1997828B1 (en) 2003-11-05 2017-10-04 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides from BCL-2 and uses thereof
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2398310T3 (es) 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
JP5783721B2 (ja) 2007-09-26 2015-09-24 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｂｃｌ−２ファミリーポリペプチドを調節する方法及び組成物
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
CA2725227A1 (en) 2008-05-06 2009-11-12 Asim Kumar Debnath Antiviral cell penetrating peptides
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
ES2666458T3 (es) 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
EP2352507A4 (en) 2008-11-24 2012-04-25 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES
US9079970B2 (en) 2008-12-09 2015-07-14 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of MCL-1
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2761568C (en) 2009-06-18 2020-10-13 Dana-Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
JP2012532929A (ja) * 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
US9227995B2 (en) 2010-04-23 2016-01-05 Øyvind Jacobsen Peptides
US9297017B2 (en) 2010-06-08 2016-03-29 University Of Washington Methods and compositions for targeted protein degradation
SG186389A1 (en) 2010-06-30 2013-01-30 Univ Brandeis Small-molecule-targeted protein degradation
JP2013532172A (ja) 2010-07-09 2013-08-15 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 安定化したインスリン分泌促進ペプチド及び使用方法
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
JP2014502152A (ja) 2010-11-12 2014-01-30 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 癌の治療及び診断
AU2011338615B2 (en) 2010-12-07 2017-07-27 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
US8762795B2 (en) 2010-12-17 2014-06-24 Microsoft Corporation Alerting recipients to errors occurring when accessing external services
WO2013036208A1 (en) 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
US9346868B2 (en) 2011-11-14 2016-05-24 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013116829A1 (en) 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9556229B2 (en) 2012-05-18 2017-01-31 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
ES2874525T3 (es) 2012-09-26 2021-11-05 Harvard College Péptidos grapados bloqueados con prolina y usos de los mismos
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR101616603B1 (ko) 2012-10-11 2016-04-28 서울대학교산학협력단 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
CN104981249B (zh) 2012-12-18 2018-06-19 英国卫生部 抗微生物化合物、它们的合成及其应用
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN106103472A (zh) 2013-10-01 2016-11-09 哈佛大学的校长及成员们 稳定化的多肽及其用途
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10682388B2 (en) 2014-01-15 2020-06-16 The Board Of Regents Of The University Of Texas System Targeting of PELP1 in cancer therapy
US10040780B2 (en) 2014-03-03 2018-08-07 The Regents Of The University Of California Mcl-1 antagonists
AU2015259191B2 (en) 2014-05-13 2019-03-21 Sangamo Therapeutics, Inc. Methods and compositions for prevention or treatment of a disease
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CN112877327B (zh) 2014-12-18 2024-11-22 综合基因技术公司 基于crispr的组合物和使用方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
EP3250691B9 (en) 2015-01-28 2023-08-02 Caribou Biosciences, Inc. Crispr hybrid dna/rna polynucleotides and methods of use
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017004591A2 (en) 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3341008B1 (en) * 2015-08-28 2026-04-15 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
WO2017040323A2 (en) * 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
JP7105696B2 (ja) 2016-02-29 2022-07-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
AU2017238390A1 (en) 2016-03-23 2018-09-27 Dana-Farber Cancer Institute, Inc. Compositions, assays, and methods for targeting HDM2 and HDMX to reverse the inhibition of p53 in pediatric cancers
EP3458101B1 (en) * 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CROMM, P. M. et al, "Targeted Protein Degradation: from Chemical Biology to Drug Discovery", Cell Chemical Biology, September 2017, vol. 24, no. 9, pages 1181-1190 *
NEKLESA, T. K. et al, "Targeted protein degradation by PROTACs", Pharmacology and Therapeutics, February 2017, vol. 174, pages 138-144 *
RICHARDSON, S. et al, 254th National Meeting and Exposition of the American Chemical Society, 2017, page 96 *

Also Published As

Publication number Publication date
US20240140999A1 (en) 2024-05-02
EP3724216A1 (en) 2020-10-21
CN112119085B (zh) 2025-04-01
US20200354413A1 (en) 2020-11-12
CN112119085A (zh) 2020-12-22
JP2023107892A (ja) 2023-08-03
AU2024200512A1 (en) 2024-02-15
AU2018385697A1 (en) 2020-04-30
WO2019118893A1 (en) 2019-06-20
JP2021506814A (ja) 2021-02-22
JP2025137626A (ja) 2025-09-19
AU2024200512B2 (en) 2026-01-08
CA3078682A1 (en) 2019-06-20
AU2026201801A1 (en) 2026-04-02
CN120118207A (zh) 2025-06-10

Similar Documents

Publication Publication Date Title
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
EP2118123B1 (en) Stabilized p53 peptides and uses thereof
AU2019218786B2 (en) Cell-permeable stapled peptide modules for cellular delivery
US12570698B2 (en) Stabilized peptides for covalent binding to target protein
EP3341008B1 (en) Peptides binding to bfl-1
US12466853B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
CA2906775A1 (en) Bh4 stabilized peptides and uses thereof
HK40126659A (zh) 稳定肽-介导的靶向蛋白降解
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)